A comparison of paroxetine and placebo in depressed outpatients

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Acta Psychiatrica Scandinavica

• Publication date

  1993-05-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1111/j.1600-0447.1993.tb03376.xPMID 8517168
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• EEG and blood level of the potential antidepressant paroxetine after a single oral dose to normal volunteers

  2004cited by this paper
• Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor

  2004cited by this paper
• Fluoxetine-induced sexual dysfunction.

  1990cited by this paper
• The psychomotor effects of paroxetine alone and in combination with haloperidol, amylobarbitone, oxazepam, or alcohol

  1989cited by this paper
• A placebo‐controlled, double‐blind, clinical trial of paroxetine in depressed outpatients

  1989cited by this paper
• An overview of the animal pharmacology of paroxetine

  1989cited by this paper
• A review of the metabolism and pharmacokinetics of paroxetine in man

  1989cited by this paper
• Metabolic pathway of paroxetine in animals and man and the comparative pharmacological properties of its metabolites

  1989cited by this paper
• New antidepressants and 5‐HT uptake inhibitors

  1989cited by this paper
• The effect of paroxetine on the quantitative EEG

  1989cited by this paper
• The clinical pharmacology of paroxetine in healthy subjects

  1989cited by this paper
• What destroys our restraints against suicide

  1988cited by this paper
• Sertraline: a new antidepressant.

  1988cited by this paper
• Changes in human whole blood 5-hydroxytryptamine (5-HT) and platelet 5-HT uptake during treatment with paroxetine, a selective 5-HT uptake inhibitor

  1987cited by this paper
• Relation between yawning behavior and central serotonergic neuronal system in rats

  1987cited by this paper
• The effect of selective 5‐hydroxytryptamine uptake inhibitors on 5‐methoxy‐N,N‐dimethyltryptamine‐induced ejaculation in the rat

  1986cited by this paper
• Stimulation of spinal serotonergic receptors facilitates seminal emission and suppresses penile erectile reflexes.

  1985cited by this paper

• Control Group Outcomes in Trials of Psilocybin, SSRIs, or Esketamine for Depression

  2025cites this paper
• Electrochemical Chemically Based Sensors and Emerging Enzymatic Biosensors for Antidepressant Drug Detection: A Review

  2023cites this paper
• Risks of Digestive System Side-Effects of Selective Serotonin Reuptake Inhibitors in Patients with Depression: A Network Meta-Analysis

  2022cites this paper
• Meta-analysis of placebo group dropout in adult antidepressant trials.

  2019cites this paper
• Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder.

  2015cites this paper
• Less is more in antidepressant clinical trials: a meta-analysis of the effect of visit frequency on treatment response and dropout.

  2013cites this paper
• Paroxetine

  2012cites this paper
• Impact of paroxetine on sleep problems in 426 cancer patients receiving chemotherapy: a trial from the University of Rochester Cancer Center Community Clinical Oncology Program.

  2012cites this paper
• Paroxetine Induced Toxic Hepatitis: Case Report

  2012cites this paper
• A Review of its Pharmacology and Therapeutic Potential in the Management of Panic Disorder

  2012cites this paper
• Comparative Efficacy of Antidepressants

  2012cites this paper
• Drug Class Review: Second-Generation Antidepressants

  2011cites this paper
• Specificity profile of paroxetine in major depressive disorder: meta-regression of double-blind, randomized clinical trials.

  2011cites this paper
• Bayesian Monitoring and Bootstrap Trial Simulation: A New Paradigm to Implement Adaptive Trial Design for Testing Antidepressant Drugs

  2009cites this paper
• Does Study Design Influence Outcome?

  2009cites this paper
• Publishing ethics in child and adolescent psychiatry: essentials for authors and readers.

  2008cites this paper
• Comparative Benefits and Harms of Second-Generation Antidepressants: Background Paper for the American College of Physicians

  2008cites this paper
• new drug applications pharmaceutical industry: review of studies in reporting from studies sponsored by Evidence b(i)ased medicine—selective

  2008cites this paper
• Serotonergic drugs as sleep medications

  2008cites this paper
• Paroxetine versus placebo and other agents for depressive disorders: a systematic review and meta-analysis.

  2007cites this paper
• Duloxetine in the treatment of major depressive disorder

  2007cites this paper
• Psychiatric Diagnosis and Clinical Trial Completion Rates: Analysis of the FDA SBA Reports

  2007influential citation
• [Comparative efficacy and tolerability of paroxetine and amitriptiline in long-term therapy preventing depressive recurrences].

  2005cites this paper
• A Mathematical Model for Paroxetine Antidepressant Effect Time Course and Its Interaction with Pindolol

  2005cites this paper
• Antidepressants and their effect on sleep

  2005cites this paper
• A review of antidepressant-induced hypomania in major depression: suggestions for DSM-V.

  2004cites this paper
• Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program.

  2003cites this paper
• Meta-Analysis of Placebo Rates in Major Depressive Disorder Trials

  2003cites this paper
• Role of Pharmacogenomics in Individualising Treatment with SSRIs

  2003cites this paper
• Evidence b(i)ased medicine—selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications

  2003cites this paper
• Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.

  2002cites this paper
• Paroxetine: an update of its use in psychiatric disorders in adults.

  2002cites this paper
• Paroxetine Associated Hepatotoxicity: A Report of 3 Cases and a Review of the Literature

  2002cites this paper
• Spotlight on Paroxetine in Psychiatric Disorders in Adults

  2002cites this paper
• Paroxetineof Its Use in Psychiatric Disorders in Adults

  2002cites this paper
• Editorial Statement

  2002cites this paper
• Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial.

  2001cites this paper
• Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial.

  2001cites this paper
• Publishing Ethics in Psychiatry

  2001cites this paper
• A Systematic Review of Newer Pharmacotherapies for Depression in Adults: Evidence Report Summary: Clinical Guideline, Part 2

  2000cites this paper
• The challenge of diagnosing depression in childhood and adolescence.

  2000cites this paper
• Chapter 23 Antidepressant and anxiolytic drugs

  2000cites this paper
• Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression

  2000cites this paper
• Anxiety with depression: a treatment need.

  1999cites this paper
• Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials.

  1999cites this paper
• Paroxetine: a Review of Clinical Experience

  1998cites this paper
• Implications of the severity of social phobia.

  1998cites this paper
• Treatment of depression--newer pharmacotherapies.

  1998cites this paper
• Efficacy studies of paroxetine in panic disorder.

  1998cites this paper
• Social phobia: epidemiology, recognition, and treatment

  1997cites this paper
• Paroxetine

  1997cites this paper
• Open-Label Treatment of Comorbid Depression and Attentional Disorders with Co-administration of Serotonin Reuptake Inhibitors and Psychostimulants in Children, Adolescents, and Adults: A Case Series

  1996cites this paper
• DEFINITION AND RESISTANT DEPRESSION EPIDEMIOLOGY OF TREATMENT

  1996cites this paper
• Definition and epidemiology of treatment-resistant depression.

  1996cites this paper
• Acute, subchronic and withdrawal sleep EEG changes during treatment with paroxetine and amitriptyline: a double-blind randomized trial in major depression.

  1995cites this paper
• Duplicate publication.

  1995cites this paper
• The SSRIs: advantages, disadvantages and differences

  1995cites this paper
• [Delay of the antidepressant effect: clinical studies].

  1995cites this paper
• Efficacy, safety, and indications for tricyclic and newer antidepressants

  1994cites this paper
• PHARMACOTHERAPY OF THE DEPRESSED PATIENT WITH CARDIOVASCULAR AND/OR CEREBROVASCULAR ILLNESS

  1994cites this paper
• Current awareness in human psychopharmacology

  year unknowncites this paper